*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

mirxes

TO KNOW. TO ACT.

Mirxes Holding Company Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2629)

(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (3) CHANGES IN COMPOSITION OF BOARD COMMITTEES; (4) NON-COMPLIANCE WITH THE LISTING RULES; (5) INSIDE INFORMATION — FURTHER DELAY IN PUBLICATION OF THE 2025 ANNUAL RESULTS AND DISPATCH OF THE 2025 ANNUAL REPORT; (6) INSIDE INFORMATION — DELAY IN PUBLICATION OF THE 2026 INTERIM RESULTS AND DISPATCH OF THE 2026 INTERIM REPORT AND (7) CONTINUED SUSPENSION OF TRADING

(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Director(s)**") of Mirxes Holding Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that on August 30, 2026, Dr. LAM Sin Lai Judy ("**Dr. Lam**") tendered her resignation as an independent non-executive Director (the "**INED**"), the chairman of the audit committee of the Company (the "**Audit Committee**"), a member of the remuneration committee of the Company (the "**Remuneration Committee**"), a member of the nomination committee of the Company (the "**Nomination Committee**") and the chairman of the independent investigation committee of the Company (the "**Independent Investigation Committee" or the "IIC")**") with effect from August 31, 2026 due to health reasons. On August 31, 2026, the Board resolved that Dr. Lam's resignation be accepted.

Dr. Lam has confirmed that she has no disagreement with the Board and that there are no matters relating to her cessation of directorship that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**").

The Board would like to express its sincere appreciation to Dr. Lam for her valuable contributions to the Company during her tenure as an INED.

(2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board further announces that on August 31, 2026, Mr. CHOW Shiu Wing Joseph ("**Mr. Chow**") was appointed as an INED with immediate effect to fill the casual vacancy resulting from Dr. Lam's resignation. As such, pursuant to the third amended and restated memorandum and articles of association of the Company (the "**Articles of Association**"), Mr. Chow shall hold office until the first annual general meeting of the Company (the "**AGM**") after his appointment, and be subject to re-election by the Shareholders at the AGM. Simultaneously with the appointment of Mr. Chow as an INED, he was appointed as the chairman of the Nomination Committee, a member of the Remuneration Committee, and a co-chairman of the Independent Investigation Committee with immediate effect.

The biographical details of Mr. Chow are set out as follows:

Mr. Chow, aged 54, obtained a bachelor's degree in law from the City University of Hong Kong in 1996 and a Postgraduate Certificate in Laws from the University of Hong Kong in 1997. He was admitted as a solicitor of the High Court of Hong Kong in October 1999, and is now a partner of Wellington Legal and a consultant in Cheung, Yeung & Lee, Solicitors. Mr. Chow has extensive experience in general commercial legal matters and has advised corporations and startups across a wide range of industries on matters pertaining to fundraising, cross-border transactions, shareholders' arrangements, technology and intellectual property matters and share option schemes. Mr. Chow holds a number of professional and honorary appointments including being vice chairman of the Hong Kong-Middle East Business Chamber and a director of the Chinese Manufacturers' Association. Mr. Chow has been acting as an independent non-executive director of Integrated Waste Solutions Group Holdings Limited (a company listed on the Stock Exchange with stock code: 923) since October 2013 and is currently an independent non-executive director of Eastern International Limited (a company listed on NASDAQ with trading symbol ELOG).

Mr. Chow's appointment has been recommended by the Nomination Committee and approved by the Board. Pursuant to the letter of appointment between Mr. Chow and the Company, the term of service of Mr. Chow shall be three years commencing on August 31, 2026, terminable by either party by one months' notice and subject to retirement by rotation and re-election at the AGM in accordance with the Articles of Association. Mr. Chow will be entitled to a director's fee of HK$345,000 per annum, plus allowance to be determined by the Board and/or the Remuneration Committee to compensate for the extra time needed for joining the Independent Investigation Committee. Mr. Chow's remuneration package has been determined by the Board with the recommendation of the Remuneration Committee with reference to, among other things, (i) his skills, knowledge and experience; and (ii) his duties and responsibilities with the Company in the present circumstances.

Mr. Chow has confirmed that as at the date of his appointment, (i) he has satisfied all the criteria for independence as set out in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"); (ii) he has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence.

Mr. Chow has confirmed to the Company that, as at the date of this announcement, he (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**"); (ii) does not hold any other positions with the Company or other members of the Group; (iii) did not hold any directorship in any public company, the securities of which are listed on any securities market in Hong Kong or overseas, nor other major appointments and professional qualifications in the last three years; and (iv) does not have any relationship with any Director, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, there is no other information relating to the appointment of Mr. Chow that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, nor are there any other matters relating to his appointment that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to welcome Mr. Chow for joining the Board.

(3) CHANGES IN COMPOSITION OF BOARD COMMITTEES

On August 31, 2026, the Board resolved to appoint: (a) Mr. TSANG Kwok Wai ("**Mr. Tsang**") as the chairman of the Audit Committee; (b) both Mr. FANG Xiao ("**Mr. Fang**") and Mr. Chow as co-chairmen of the Independent Investigation Committee; (c) Mr. Chow as the chairman of the Nomination Committee; and (d) Mr. Chow as a member of the Remuneration Committee, in each case with immediate effect.

The Board congratulates Mr. Tsang, Mr. Fang and Mr. Chow on their new roles.

(4) NON-COMPLIANCE WITH THE LISTING RULES

As a result of the resignation of Dr. Lam on August 31, 2026, the Company is unable to comply with the following requirements under the Listing Rules:

(a) the requirement under Rule 13.92(2) of the Listing Rules to have directors of different genders on the board; and

(b) the requirement under paragraph B.3.5 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules which stipulates that the listed issuer must appoint at least one director of a different gender to the nomination committee.

The Company is in the process of identifying a suitable female candidate to be appointed to the Board and the Nomination Committee as soon as practicable, and in any event within three months from the date of resignation of Dr. Lam in order to ensure compliance by the Company with the requirements of the Listing Rules as set out above. Further announcement will be made by the Company in this regard as and when appropriate.

(5) INSIDE INFORMATION — FURTHER DELAY IN PUBLICATION OF THE 2025 ANNUAL RESULTS AND DISPATCH OF THE 2025 ANNUAL REPORT

Sections (5) and (6) of this announcement are disclosed by the Company pursuant to Rules 13.09(2), 13.48(1), 13.49(3) and 13.49(6) of the Listing Rules and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the SFO).

Reference is made to the announcements of the Company dated March 31, 2026, April 2, 2026, April 30, 2026, May 10, 2026 and July 1, 2026 (collectively, the "**Announcements**") in relation to, amongst others, the delay in publication of the annual results announcement and delay in dispatch of the annual report for the year ended December 31, 2025, the establishment of the IIC, the suspension of trading in the shares of the Company, the Outstanding Audit Matters, the Resumption Guidance and the quarterly update on resumption progress. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

As disclosed in the Announcements, completion of the audit of the 2025 Annual Results is subject to the resolution of the Outstanding Audit Matters, which is in turn subject to the outcome of the Investigation. The publication of the 2025 Annual Results will be further delayed as additional time is required for the IIC to ensure that independent professional advisers will conduct sufficient and necessary work to complete the Investigation with the view to addressing the Outstanding Audit Matters in alignment with the Resumption Guidance. The Company is actively cooperating with the IIC as regards the Investigation, so that it can resume work on the 2025 Annual Results and the 2025 Annual Report as soon as possible. Further announcement(s) will be made by the Company regarding any material development in connection with the 2025 Annual Results and the 2025 Annual Report, including the expected dates of publication and dispatch, as and when appropriate.

(6) INSIDE INFORMATION — DELAY IN PUBLICATION OF THE 2026 INTERIM RESULTS AND DISPATCH OF THE 2026 INTERIM REPORT

Pursuant to Rules 13.48(1) and 13.49(6) of the Listing Rules, the Company is required to publish an announcement in relation to its preliminary results for the six months ended June 30, 2026 (the "**2026 Interim Results**") not later than two months after the end of the relevant financial period (i.e. on or before August 31, 2026) and to dispatch its interim report for the six months ended June 30, 2026 (the "**2026 Interim Report**") to the Shareholders not more than three months after the end of the relevant financial period (i.e. on or before September 30, 2026). In view of the further delay of the publication of the 2025 Annual Results as explained above, the preparation of the 2026 Interim Results (including the opening balances) cannot be finalized.

Accordingly, the Company is unable to publish the 2026 Interim Results by the end of August 2026, and unable to dispatch the 2026 Interim Report by the end of September 2026. The Company will publish further announcement(s) to inform the Shareholders of any material development regarding the 2026 Interim Results and the 2026 Interim Report, including the expected dates of publication and dispatch, as and when appropriate.

(7) CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange was suspended from 9:00 a.m. on April 1, 2026 and will remain suspended pending the fulfillment of the Resumption Guidance as specified by the Stock Exchange.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.

By Order of the Board
Mirxes Holding Company Limited
Dr. ZHOU Lihan
Executive Director and Chief Executive Officer

Hong Kong, September 1, 2026

As of the date of this announcement, the Board comprises (i) Dr. ZHOU Lihan and Dr. ZOU Ruiyang as executive Directors; (ii) Dr. TOO Heng Phon, Dr. LE Beilin and Mr. LIU Da as non-executive Directors; and (iii) Mr. FANG Xiao, Mr. TSANG Kwok Wai and Mr. CHOW Shiu Wing Joseph as independent non-executive Directors.